trending Market Intelligence /marketintelligence/en/news-insights/trending/rkuxgjjhyuzg39jw60n5da2 content esgSubNav
In This List

Celyad prices $47.3M global offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Celyad prices $47.3M global offering

Celyad SA priced an offering of 523,913 American depositary shares at $26.28 each.

The Belgian biopharmaceutical company is also looking to sell 1,276,087 common shares at €22.29 apiece.

All in all, the company expects to raise $47.3 million in a global offering that closes May 22.

Wells Fargo Securities LLC and Bryan Garnier & Co. are acting as the joint book-running managers for the offering.

Bank Degroof Petercam NV and LifeSci Capital LLC are acting as co-managers for the offering. Kempen & Co. NV is Celyad's adviser in the offering.

The offering's underwriters can buy an additional 270,000 shares from the company.